The American Society of Clinical Oncology (ASCO) i

The American Society of Clinical Oncology (ASCO) is having their annual meeting in Chicago. It would be great if CytoDyn could present at the 2025 annual meeting. Medpage Today has a list of reports available on their website at this link.

https://www.medpagetoday.com/meetingcoverage/asco

Here is a report that was published today about liver transplantation in CRC. You can read it at this link.

https://www.medpagetoday.com/meetingcoverage/asco/110469

Here are some excerpts:

A Win for Liver Transplantation in Unresectable Metastatic Colorectal Cancer

Liver transplantation for unresectable colorectal cancer (CRC) liver metastases led to dramatic improvement in long-term survival, French investigators reported.

Five-year overall survival (OS) increased from 13% with standard-of-care chemotherapy to 57% with transplantation and chemotherapy. Progression-free survival (PFS) at 3 and 5 years showed large differences favoring the transplant group (33% vs 4%, 20% vs 0%, respectively). A subgroup of patients who had rescue surgery for recurrence after transplantation had a 5-year PFS of 36%, reported Rene Adam, MD, of Paul Brousse Hospital in Villejuif, France, at the American Society of Clinical Oncology (ASCO) meeting.

These results were obtained through a rigorous patient selection and prioritization for organ allocation," said Adam. "Transplanted patients for colorectal liver metastases have a similar survival as those transplanted for established liver transplant indications. Liver transplantation plus chemotherapy offers a potential of cure to cancer patients with otherwise poor long-term outcome."

The most striking finding from the French study is a per-protocol analysis showing a 5-year OS of 73% in the transplant cohort versus 9% with chemotherapy only.

Two other studies reported at ASCO addressed other CRC liver metastases settings. A comparison of thermal ablation and surgery for resectable liver metastases showed that ablation led to lower morbidity and mortality and at least similar oncologic outcomes. In the other, surgical debulking prior to palliative chemotherapy did not improve survival in patients with disseminated liver metastases.

In the introduction to the TransMet results, Adam noted that chemotherapy is standard of care for definitively unresectable CRC liver metastases. Although efficacy has improved, chemotherapy offers "almost no chance" of long-term survival.